BRPI0510148A - vacina para doença peridental - Google Patents

vacina para doença peridental

Info

Publication number
BRPI0510148A
BRPI0510148A BRPI0510148-4A BRPI0510148A BRPI0510148A BR PI0510148 A BRPI0510148 A BR PI0510148A BR PI0510148 A BRPI0510148 A BR PI0510148A BR PI0510148 A BRPI0510148 A BR PI0510148A
Authority
BR
Brazil
Prior art keywords
periodontal disease
vaccine
kits
detecting
treating
Prior art date
Application number
BRPI0510148-4A
Other languages
English (en)
Inventor
Kimberly Jean Dreier
John Morgan Hardham
John David Haworth
Kendall Wayne King
Rajendra Krishnan
David Ross Mcgavin
Original Assignee
Pfizer Prod Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Prod Inc filed Critical Pfizer Prod Inc
Publication of BRPI0510148A publication Critical patent/BRPI0510148A/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/0216—Bacteriodetes, e.g. Bacteroides, Ornithobacter, Porphyromonas
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/0208—Specific bacteria not otherwise provided for
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/155—Paramyxoviridae, e.g. parainfluenza virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/155—Paramyxoviridae, e.g. parainfluenza virus
    • A61K39/175—Canine distemper virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/215—Coronaviridae, e.g. avian infectious bronchitis virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/23—Parvoviridae, e.g. feline panleukopenia virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/235—Adenoviridae
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/52—Bacterial cells; Fungal cells; Protozoal cells
    • A61K2039/521—Bacterial cells; Fungal cells; Protozoal cells inactivated (killed)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
    • A61K2039/552—Veterinary vaccine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55572—Lipopolysaccharides; Lipid A; Monophosphoryl lipid A
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55577—Saponins; Quil A; QS21; ISCOMS
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/70—Multivalent vaccine
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011—Details
    • C12N2750/14011—Parvoviridae
    • C12N2750/14034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/18011—Paramyxoviridae
    • C12N2760/18411—Morbillivirus, e.g. Measles virus, canine distemper
    • C12N2760/18434—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/18011—Paramyxoviridae
    • C12N2760/18611—Respirovirus, e.g. Bovine, human parainfluenza 1,3
    • C12N2760/18634—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/16011—Caliciviridae
    • C12N2770/16034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Organic Chemistry (AREA)
  • Pulmonology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Communicable Diseases (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Oncology (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Fodder In General (AREA)
  • Peptides Or Proteins (AREA)

Abstract

VACINA PARA DOENçA PERIDENTAL. A presente invenção refere-se aos novos isolados bacterianos identificados por seu DNA de rNA de 16S, que causam doença peridental em animais de companhia, seqüências de polinucleotídeo neles contidas, polipeptídeos codificados por tais seqüências de polinucleotídeo e vacinas compreendendo tais bactérias, polinucleotídeos ou polipeptídeos.Também fornecidos são métodos para tratar e prevenir doença peridental e kits para detectar e tratar kits de doença peridental para detectar e prevenir doença peridental. Além disso, métodos para avaliar a eficácia de uma vacina contra doenças peridentais em um animal são fornecidos.
BRPI0510148-4A 2004-05-21 2005-03-21 vacina para doença peridental BRPI0510148A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US10/851,965 US7378101B2 (en) 2001-12-21 2004-05-21 Vaccine for periodontal disease
PCT/IB2005/000822 WO2005112993A1 (en) 2004-05-21 2005-03-21 Vaccine for periodontal disease

Publications (1)

Publication Number Publication Date
BRPI0510148A true BRPI0510148A (pt) 2007-10-02

Family

ID=35058733

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0510148-4A BRPI0510148A (pt) 2004-05-21 2005-03-21 vacina para doença peridental

Country Status (19)

Country Link
US (2) US7378101B2 (pt)
EP (1) EP1753454B1 (pt)
JP (1) JP4099213B2 (pt)
CN (1) CN101014363A (pt)
AR (1) AR048347A1 (pt)
AT (1) ATE432082T1 (pt)
AU (1) AU2005244663A1 (pt)
BR (1) BRPI0510148A (pt)
CA (1) CA2565925C (pt)
DE (1) DE602005014635D1 (pt)
ES (1) ES2325737T3 (pt)
IL (1) IL178971A0 (pt)
MX (1) MXPA06013471A (pt)
NO (1) NO20065064L (pt)
NZ (1) NZ550981A (pt)
RU (1) RU2364417C2 (pt)
TW (1) TW200538152A (pt)
WO (1) WO2005112993A1 (pt)
ZA (1) ZA200609105B (pt)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8129500B2 (en) * 1997-12-10 2012-03-06 Csl Limited Porphyromonas gingivalis polypeptides and nucleotides
US7378101B2 (en) * 2001-12-21 2008-05-27 Pfizer, Inc. Vaccine for periodontal disease
US7682619B2 (en) 2006-04-06 2010-03-23 Cornell Research Foundation, Inc. Canine influenza virus
US9181592B2 (en) * 2007-03-30 2015-11-10 Case Western Reserve University Method for detecting a bacterial pathogen
WO2008137506A2 (en) * 2007-05-01 2008-11-13 Mars Incorporated Methods and kits for dog plaque disease
JP2009173558A (ja) * 2008-01-22 2009-08-06 Gen Corp:Kk 抗イヌ歯周病組成物
US8691502B2 (en) 2008-10-31 2014-04-08 Tremrx, Inc. T-cell vaccination with viral vectors via mechanical epidermal disruption
US9107859B2 (en) * 2009-09-10 2015-08-18 Merial, Inc. Vaccine formulations comprising saponin-containing adjuvants
US20120231033A1 (en) * 2009-12-01 2012-09-13 Carla Christina Schrier Inactivated poultry vaccine
WO2012151272A2 (en) * 2011-05-02 2012-11-08 Tremrx, Inc. T-cell vaccination with viral vectors via mechanical epidermal disruption
US9402894B2 (en) 2011-10-27 2016-08-02 International Aids Vaccine Initiative Viral particles derived from an enveloped virus
US20140335121A1 (en) * 2011-12-13 2014-11-13 School Corporation, Azabu Veterinary Medicine Educational Institution Fimbriae type of prophyromonas gulae
US9347065B2 (en) 2012-03-29 2016-05-24 International Aids Vaccine Initiative Methods to improve vector expression and genetic stability
JPWO2015190589A1 (ja) * 2014-06-13 2017-04-20 学校法人麻布獣医学園 イヌの僧帽弁閉鎖不全症のリスク診断
JP2018154574A (ja) * 2017-03-16 2018-10-04 合同会社チューモス 点眼ワクチン及び免疫誘導方法
SG11202003147XA (en) 2017-10-12 2020-05-28 Vaxcyte Inc Periodontitis vaccine and related compositions and method of use
US12403187B2 (en) 2018-12-31 2025-09-02 Bellevacc As Bacterial vaccine
CN112533623A (zh) 2019-07-04 2021-03-19 株式会社索辛 动物用的口腔用组合物及使用了它的动物用的牙周病预防剂、传染病预防剂及口臭预防剂
US10973908B1 (en) 2020-05-14 2021-04-13 David Gordon Bermudes Expression of SARS-CoV-2 spike protein receptor binding domain in attenuated salmonella as a vaccine
US12537071B1 (en) 2020-07-22 2026-01-27 David Gordon Bermudes Bacteria having boolean control pathways expressing therapeutic proteins including immunotherapeutic cytotoxins
CN116751292B (zh) * 2023-07-31 2024-05-14 河南大学 牙龈卟啉单胞菌Mfa1单克隆抗体及其应用

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS59128338A (ja) 1982-12-08 1984-07-24 Kitasato Inst:The 歯周炎予防用ワクチン及びその製法
JPH0662431B2 (ja) 1984-12-14 1994-08-17 ライオン株式会社 歯周炎予防用経口ワクチン
US5536497A (en) 1992-12-21 1996-07-16 The Research Foundation Of State University Of New York Fimbrial polypeptides useful in the prevention of periodontitis
JPH0797395A (ja) 1993-09-28 1995-04-11 Kyowa Medex Co Ltd ポルフイロモナス・ジンジバリス線毛蛋白質の配列を含有するペプチド類及びその用途
WO1995010612A1 (en) 1993-10-08 1995-04-20 Lion Corporation FIMBRILLIN PROTEIN OF $i(PORPHYROMONAS GINGIVALIS)
US5563063A (en) 1995-08-30 1996-10-08 Nihon University (Educational Foundation) Porphyromonas crevioricanis species of microorganism
US5710039A (en) 1995-08-30 1998-01-20 Nihon University (Educational Foundationn) Porphyromonas gingivicanis strain ATCC 55562
AUPQ137699A0 (en) * 1999-07-02 1999-07-22 University Of New England, The Control of acidosis
AUPQ718200A0 (en) 2000-04-28 2000-05-25 Csl Limited Porphyromonas gingivalis recombinant proteins and truncations
US7378101B2 (en) * 2001-12-21 2008-05-27 Pfizer, Inc. Vaccine for periodontal disease
US7468185B2 (en) * 2001-12-21 2008-12-23 Pfizer Inc. Vaccine for periodontal disease

Also Published As

Publication number Publication date
ES2325737T3 (es) 2009-09-15
CN101014363A (zh) 2007-08-08
US20080311151A1 (en) 2008-12-18
IL178971A0 (en) 2007-03-08
CA2565925C (en) 2011-01-18
MXPA06013471A (es) 2007-01-23
JP2008500379A (ja) 2008-01-10
AR048347A1 (es) 2006-04-19
JP4099213B2 (ja) 2008-06-11
ATE432082T1 (de) 2009-06-15
US7378101B2 (en) 2008-05-27
TW200538152A (en) 2005-12-01
ZA200609105B (en) 2008-12-31
CA2565925A1 (en) 2005-12-01
RU2364417C2 (ru) 2009-08-20
DE602005014635D1 (de) 2009-07-09
NZ550981A (en) 2009-07-31
EP1753454B1 (en) 2009-05-27
WO2005112993A1 (en) 2005-12-01
RU2006140984A (ru) 2008-05-27
NO20065064L (no) 2006-12-01
EP1753454A1 (en) 2007-02-21
AU2005244663A1 (en) 2005-12-01
US20050010032A1 (en) 2005-01-13

Similar Documents

Publication Publication Date Title
BRPI0510148A (pt) vacina para doença peridental
BR0205775A (pt) Vacina para a doença periodontal
BRPI0407207A (pt) Método para tratar, prevenir e diagnosticar uma infecção por heliocobacter
EP2528931A4 (en) CYCLOVIRUS AND USE METHOD THEREFOR
NO20082448L (no) Kombinasjoner av angiopoietin-2 antagonister og VEGF-A, KDR og/eller FLT1 antagonist for behandling av cancer
ATE492639T1 (de) Multimer zur immunstimulation
EA201100413A1 (ru) Способ лечения бактериальной инфекции
BRPI0606363A2 (pt) método para o isolamento e/ou a purificação de ácidos nucleicos ácido nucleico, e, método para a imobilização de ácidos nucleicos em uma matriz
BR112012009366A2 (pt) toxina rtx citolítica de gallibacterium anatis
ATE534902T1 (de) Replikationsproteinn ciz1
WO2006046017A3 (en) Vaccine and nucleic acids capable of protecting poultry against colonisation by campylobacter
ATE482976T1 (de) Defensinproteine
FI20022064A0 (fi) Nukleiinihappokoettimia, universaaleja alukkeita ja menetelmiä, joissa niitä käytetään
BRPI0520510A2 (pt) composições antimicrobiais e seus processos associados
BRPI0415742A (pt) vacina para a doença periodontal
Soto-Rodriguez et al. Prevalence of pathogenic bacteria detected by qPCR from cultured Nile tilapia (Oreochromis niloticus Linnaeus, 1758) in southwest Mexico
DE60327462D1 (de) Nachweis, identifizierung und differenzierung von eubakterien unter verwendung eines hybridisierungs-assays
BRPI0607473A2 (pt) infecção por helicobacter em suìnos
GB0423126D0 (en) Protein
ATE526400T1 (de) Metalloproteaseproteine
KR20090047123A (ko) 꿀벌 유럽부저병 진단용 특이 프라이머 및 그 진단방법
WO2007108903A3 (en) Campylobacter vaccines and methods of use
SE9902489D0 (sv) Mutated Nurr1 gene
Suelam Isolation and Identification of Arcobacter species Recovered from Rabbits in Zagazig, Egypt
Chrisostom et al. Implications of multiple risk factors for delineation of disease control zones: case study on foot-and-mouth disease occurrence in Uganda.

Legal Events

Date Code Title Description
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 9A ANUIDADE.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2260 DE 29/04/2014.